Catalyst Dossier · compiled by CeliA 🧫

Alkermes plc (ALKS)

Pharmaceutical Preparations · market cap $7.5B · as of 2026-06-27

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-04

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Alkermes plc (ALKS) is a fully-integrated Dublin-headquartered biopharma focused on psychiatric and neurological disorders, with ~2,100 employees and a market cap of ~$8.8B. The company generates meaningful commercial revenue (~$1.5B in 2025) anchored by established products including VIVITROL, while maintaining a deep late-stage pipeline spanning schizophrenia, addiction, MDD, and narcolepsy. A cluster of high-importance Phase 3 readouts — notably OLZ/SAM and ALKS 3831 in schizophrenia (est. September 2026) and ALKS 2680 in narcolepsy (2027) — define the near-term catalytic arc.

The catalyst path

2026-08-04Earningsimp 5/10
2026-09-15 (est.)Phase 3 · ALKS 3831imp 9/10
2026-11-15 (est.)Phase 2 · ALKS 2680imp 7/10
2027-05-15 (est.)Phase 3 · ALKS 2680 Dose 2imp 9/10
2027-05-15 (est.)Phase 3 · ALKS 2680 Dose 1imp 9/10
2027-05-15 (est.)Phase 3 · ALKS 2680 Dose 3imp 9/10
2027-06-15 (est.)Phase 3 · ALKS 2680 Dose 1imp 9/10

Pipeline

Asset	Phase	Indication
VIVITROL® 380 mg	Phase 3	Opiate Dependence
Olanzapine	Phase 3	Schizophrenia
Medisorb naltrexone 380 mg	Phase 3	Opiate Dependence
Medisorb naltrexone 190 mg	Phase 3	Alcohol Dependence
High Dose ALKS 5461	Phase 3	Major Depressive Disorder
ALKS 9072, Low Dose	Phase 3	Schizophrenia
N1539	Phase 2	Hysterectomy
Paliperidone Palmitate	Phase 3	Schizophrenia
ALKS 3831	Phase 3	Schizophrenia
ALK3831	Phase 3	Schizophrenia
OLZ/SAM	Phase 3	Schizophrenia
VIVITROL 380 mg	Phase 3	Alcohol Dependence
ALKS 37	Phase 2	Opioid-induced Constipation
ALKS 5461	Phase 3	Major Depressive Disorder
ALKS 9072	Phase 3	Schizophrenia
ALKS 2680	Phase 2	Narcolepsy Type 2
NTX/BUP	Phase 3	Opioid Use Disorder
Samidorphan (Low Dose)	Phase 2	Schizophrenia
Motrin	Phase 2	Dental Pain
ALKS 9072, Low	Phase 3	Schizophrenia

Price & technical context

3-month

+46.3%

6-month

+84.6%

12-month

+80.8%

52-wk range

$26.13–$55.08

vs 50-day MA

+27.4%

vs 200-day MA

+56.3%

Realized vol

41.4%

Max drawdown

-27.4%

Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for ALKS (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.